Filter
179
Text search:
European
Monitoring
Centre
for
Drugs
and
Drug
Addiction
Featured
13
22
Language
Document type
141
14
12
6
2
2
1
1
Countries / Regions
28
14
12
7
5
4
3
3
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
18
10
10
2
Toolboxes
77
41
28
3
2
2
1
1
1
1
AIDSTAR-One | CASE STUDY SERIES November 2012
Accessed: 07.11.2019
Mapping Report - Ireland.
Background: Cardiovascular disease (CVD), mainly heart attack and stroke, is the
leading cause of premature mortality in low and middle income countries (LMICs).
Identifying
...
A Provisional Document. The purpose of this manual is to provide guidance to public health professionals tasked with managing a response to viral hepatitis. As every country’s needs are different with respect to its epidemiology and the current le
...
Single TB and HIV Concept Note Albania 2016-2018 27 April 2015
Tokar et al. Health Research Policy and Systems (2019) 17:23 https://doi.org/10.1186/s12961-019-0415-4
In 2016, the risk of premature mortality1 from noncommunicable diseases (NCDs) in Ethiopia was 18.3%. The economic costs of NCDs are significant and are due principally to their impact on the non-health sector (reduced workforce
...
Inequality of access to palliative care and symptom relief is one of the greatest disparities in global health care (1). Currently, there is avoidable suffering on a massive scale due to lack of access to palliative care
...
Evaluation report
September 2014
WHO guideline on balanced national controlled medicines policies to ensure medical access and safety
Access to medicines is essential for attainment of universal health coverage, which is central to achievement of the health-related Sustainable Development Goals. Controlled medicines include those such as opioids, benzodiazepines, barbiturates, amp
...
Joint Stakeholder Submission
Accessed: 29.09.2019
The power of the Global Drug Policy Index lies in its key objective: to score and
rank how countries are faring in different areas of drug policy
...
Evaluation report November 2014
Evaluation report
December 2014
March 2015
